Otenabant
Otenabant[edit | edit source]
Otenabant is a pharmaceutical drug that was developed as a cannabinoid receptor antagonist. It was primarily investigated for its potential use in the treatment of obesity and related metabolic disorders. Otenabant acts by blocking the CB1 receptor, which is part of the endocannabinoid system.
Mechanism of Action[edit | edit source]
Otenabant functions as a selective antagonist of the CB1 receptor, which is predominantly found in the central nervous system and peripheral tissues. By inhibiting the action of endogenous cannabinoids at this receptor, Otenabant reduces appetite and food intake, which can lead to weight loss. The blockade of CB1 receptors also affects lipid metabolism and glucose homeostasis, contributing to its potential benefits in treating metabolic syndrome.
Development and Clinical Trials[edit | edit source]
Otenabant was developed by Pfizer, a major pharmaceutical company. During its development, Otenabant underwent several clinical trials to assess its efficacy and safety in humans. These trials aimed to determine the drug's impact on body weight, metabolic parameters, and potential side effects.
Side Effects[edit | edit source]
Like other CB1 receptor antagonists, Otenabant was associated with several side effects. Common adverse effects included nausea, dizziness, and anxiety. More serious concerns were raised about the potential for psychiatric disorders, such as depression and suicidal ideation, which ultimately led to the discontinuation of its development.
Discontinuation[edit | edit source]
The development of Otenabant was halted due to safety concerns, particularly the risk of psychiatric side effects. This decision was influenced by the withdrawal of similar drugs from the market, such as Rimonabant, which faced similar issues. As a result, Otenabant did not receive regulatory approval and was never marketed.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
